WallStreetZenWallStreetZen

NASDAQ: LABT
Lakewood Amedex Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LABT

Based on 1 analyst offering 12 month price targets for Lakewood Amedex Biotherapeutics Inc

Min Forecast
$3.00+1,165.82%
Avg Forecast
$3.00+1,165.82%
Max Forecast
$3.00+1,165.82%

Should I buy or sell LABT stock?

Based on 1 analyst offering ratings for Lakewood Amedex Biotherapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LABT stock forecasts and price targets.

LABT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-28

1 of 1

Forecast return on equity

Is LABT forecast to generate an efficient return?

Company
64.74%
Industry
-16.81%
Market
154.98%
LABT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LABT forecast to generate an efficient return on assets?

Company
56.53%
Industry
-3.72%
LABT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LABT earnings per share forecast

What is LABT's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$5.06
Avg 2 year Forecast
$1.35
Avg 3 year Forecast
$1.18

LABT revenue forecast

What is LABT's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

LABT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LABT$0.24$3.00+1,165.82%Buy
VBIO$0.62N/AN/A
HLSQ$0.18N/AN/A
JAGX$2.04N/AN/A
SPRC$0.71N/AN/A
View Top Biotech Stocks

Lakewood Amedex Biotherapeutics Stock Forecast FAQ

Is Lakewood Amedex Biotherapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LABT) stock is to Buy LABT stock.

Out of 1 analyst, 0 (0%) are recommending LABT as a Strong Buy, 1 (100%) are recommending LABT as a Buy, 0 (0%) are recommending LABT as a Hold, 0 (0%) are recommending LABT as a Sell, and 0 (0%) are recommending LABT as a Strong Sell.

If you're new to stock investing, here's how to buy Lakewood Amedex Biotherapeutics stock.

What is LABT's earnings growth forecast for 2026-2028?

(NASDAQ: LABT) Lakewood Amedex Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.02%.

Lakewood Amedex Biotherapeutics's earnings in 2026 is -$7,347,376.On average, 3 Wall Street analysts forecast LABT's earnings for 2026 to be $11,988,726, with the lowest LABT earnings forecast at $11,518,579, and the highest LABT earnings forecast at $12,341,335. On average, 3 Wall Street analysts forecast LABT's earnings for 2027 to be $3,190,548, with the lowest LABT earnings forecast at $3,065,428, and the highest LABT earnings forecast at $3,284,388.

In 2028, LABT is forecast to generate $2,803,815 in earnings, with the lowest earnings forecast at $2,693,861 and the highest earnings forecast at $2,886,280.

What is LABT's revenue growth forecast for 2026-2028?

(NASDAQ: LABT) Lakewood Amedex Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.

Lakewood Amedex Biotherapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast LABT's revenue for 2026 to be $0, with the lowest LABT revenue forecast at $0, and the highest LABT revenue forecast at $0. On average, 3 Wall Street analysts forecast LABT's revenue for 2027 to be $0, with the lowest LABT revenue forecast at $0, and the highest LABT revenue forecast at $0.

In 2028, LABT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is LABT's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: LABT) forecast ROA is 56.53%, which is higher than the forecast US Biotechnology industry average of -3.72%.

What is LABT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LABT price target, the average LABT price target is $3.00, with the highest LABT stock price forecast at $3.00 and the lowest LABT stock price forecast at $3.00.

The Wall Street analyst predicted that Lakewood Amedex Biotherapeutics's share price could reach $3.00 by Oct 28, 2027. The average Lakewood Amedex Biotherapeutics stock price prediction forecasts a potential upside of 1,165.82% from the current LABT share price of $0.24.

What is LABT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LABT) Lakewood Amedex Biotherapeutics's current Earnings Per Share (EPS) is -$11.35. On average, analysts forecast that LABT's EPS will be $5.06 for 2026, with the lowest EPS forecast at $4.86, and the highest EPS forecast at $5.21. On average, analysts forecast that LABT's EPS will be $1.35 for 2027, with the lowest EPS forecast at $1.29, and the highest EPS forecast at $1.39. In 2028, LABT's EPS is forecast to hit $1.18 (min: $1.14, max: $1.22).

What is LABT's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: LABT) forecast ROE is 64.74%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.